Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice.

This publication has 16 references indexed in Scilit:

• Treatment of cancer of the head and neck
  CA: A Cancer Journal for Clinicians, 1995
• Interleukins and Contrasuppression Induce Immune Regression of Head and Neck Cancer
  JAMA Otolaryngology–Head & Neck Surgery, 1994
• Basic science reviews: Immunomodulation therapy for squamous cell carcinoma of the head and neck
  Head & Neck, 1993
• Basic science reviews. Immunology of head and neck cancer: Perspectives
  Head & Neck, 1993
• Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
  The Journal of Experimental Medicine, 1992
• Hierarchical Immunosuppression of Regional Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma
  Otolaryngology -- Head and Neck Surgery, 1991
• Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor.
  Proceedings of the National Academy of Sciences, 1991
• The Effect of Preoperative Local Interleukin-2 (IL-2) Injections in Patients with Head and Neck Squamous Cell Carcinoma: An Immunological Study
  Acta Oto-Laryngologica, 1991
• Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.
  The Journal of Experimental Medicine, 1989
• Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro
  Cellular Immunology, 1988